VC-Inflazome appoints chief medical officer
Dublin, Ireland-based Inflazome, a developer of small molecule drugs that block harmful inflammation, has named Dr. Thomas Jung as chief medical officer. Jung is the former head of the translational medicine group for Novartis Europe. Inflazome is backed by Forbion Capital Partners, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.
29 November 2018•3 mins read
